# Diabetes Research Hub — Monitor Review Report

**Run date:** 2026-06-15 (automated, scheduled)
**Reviewer:** Hub Monitor (automated read-only review)
**Prepared for:** Justin Bottum

---

## TL;DR — What's actually actionable

1. **A tracked therapy was FDA-approved 2 days ago.** Teplizumab (Tzield, Sanofi) approved June 13 for **children 8+ with stage 3 T1D**. The hub already has `teplizumab_sNDA_decision_prep.md` — that prep doc is now resolved and should be marked closed/updated. [Certain — STAT, dated 2026-06-13]
2. **Two more tracked therapies posted Phase 3 data at ADA 2026 (June 6–7).** Retatrutide (TRIUMPH-1) and Novo's Reimagine once-weekly insulin program. Neither is yet reflected in the hub's trial notes. [Certain]
3. **Data pipelines are mostly current, with one real staleness problem:** the literature gap analysis underlying data (`literature_gap_data.json`) is from **2026-04-20 (56 days old)** even though the report wrapper was regenerated June 14. The gap rankings are running on 8-week-old PubMed counts.
4. **No clinical-trial status changes or new results** in the daily diff (Jun 14→15). The trial dataset is being refreshed but is not surfacing change — that's expected, not a problem.

---

## File System Status

| Item | Status |
|------|--------|
| Workspace folder | Found — `Diabetes_Research`, all expected paths present |
| `Analysis/Results/` | Present (342 files) |
| `RESEARCH_DOCTRINE.md` | Present |
| `CONTRIBUTION_STRATEGY.md` | Present |
| `Diabetes_Research_Tracker.xlsx` | Present (⚠ lock file `.~lock.Diabetes_Research_Tracker.xlsx#` exists — file may be open in Excel) |

**Freshness of key outputs:**

| File | Last modified | Age | Note |
|------|--------------|-----|------|
| `clinical_trials_latest.json` | 2026-06-15 07:05 | 0 d | Current |
| `clinical_trials_summary.md` | 2026-06-15 07:05 | 0 d | Current |
| `hub_monitor_report.md` | 2026-06-15 07:07 | 0 d | Current |
| `pubmed_recent_latest.json` | 2026-06-12 07:05 | 3 d | Slightly stale — `baseline_pubmed_alerts.py` last ran Jun 12 |
| `literature_gap_report.md` | 2026-06-14 14:07 | 1 d | Wrapper fresh… |
| `literature_gap_data.json` | **2026-04-20 15:35** | **56 d** | …but underlying data is 8 weeks old |

Hub monitor flagged **716 result files older than 14 days** — that is mostly the daily snapshot archive (90+ dated trial/pubmed snapshots) and is expected. No action needed on the archive itself.

---

## Clinical Trial Changes

**Daily diff (2026-06-14 → 2026-06-15):** 0 new, 0 removed, 0 status changes, 0 new results. Stable.

**6-day window (2026-06-09 → 2026-06-15):** 6 new trials, all `NOT_YET_RECRUITING`, all device/stimulation/AID feasibility studies (Yuwell CGM accuracy, Ideal Medical ICU closed-loop, vagus-nerve stimulation, Steno AID-vs-MDI, Boston Scientific endoscopic sleeve gastroplasty). None Phase 3, none from key cell/immunotherapy sponsors. Low priority.

**30-day window (2026-05-16 → 2026-06-15):** 33 new trials, 5 Phase 3 — most notable:
- **NCT05813912** (Novo Nordisk) — once-weekly insulin study, now **COMPLETED**, results posted 2026-06-03
- **NCT07613307** (Eli Lilly) — new **orforglipron** Phase 3 (not-yet-recruiting)
- **NCT04965935** (University Health Network) — SGLT2 inhibitor study, now COMPLETED

**Key Phase 3 trials for tracked therapies (current status):**

| Therapy | Sponsor | Phase 3 trials | Notable status |
|---------|---------|---------------|----------------|
| VX-880 (zimislecel) | Vertex | NCT04786262, NCT06832410 | Both **RECRUITING** |
| Teplizumab | Sanofi | NCT07088068 (RECRUITING), NCT05757713 (P4) | **FDA-approved peds 6/13** (see Breaking News) |
| Baricitinib | Eli Lilly | NCT07222332, NCT07222137 | Both **RECRUITING** (T1D repurposing — Tier 1 relevant) |
| Orforglipron | Eli Lilly | 5 trials incl. NCT05971940 **COMPLETED** | New P3 NCT07613307 added |
| Retatrutide | Eli Lilly | NCT06297603, NCT06260722, NCT05929079 | Active; **TRIUMPH-1 data at ADA** |
| CagriSema | Novo Nordisk | NCT06534411, NCT07564414, NCT07282613 | Recruiting / not-yet |

**Recently posted results worth a look (since 2026-05-15):** 12 trials posted results. Most relevant:
- **NCT04426474** (Eli Lilly, LY3502970 / orforglipron in T2D) — results posted 2026-05-26
- **NCT05813912** (Novo Nordisk, weekly insulin) — results posted 2026-06-03
- **NCT04167761** (Stanford, ertugliflozin epicardial fat) — 2026-06-04

Totals: 809 unique trials, 262 recruiting, 46 Phase 3 recruiting.

---

## PubMed Highlights

Source: `pubmed_recent_latest.json` (generated 2026-06-12, 30-day lookback, 165 unique papers, 16 domains).

**Cross-domain papers (highest value — 13 of 165):**

| PMID | Domains | Title (short) |
|------|---------|---------------|
| 42163482 | T1D Stem Cell + T1D Immunotherapy + teplizumab | EV proteins as predictive biomarkers for developing T1D |
| 42259339 | orforglipron + dapagliflozin | Orforglipron vs dapagliflozin head-to-head in T2D |
| 42264536 | T2D GLP-1 + retatrutide | Retatrutide triple-acting agent for T2D |
| 42198313 | retatrutide + CagriSema | Diabetes & stroke — therapeutic potential of incretins |
| 42277427 | T2D GLP-1 + Gene Therapy | Lentiviral GLP-1 gene therapy, β-cell regeneration |
| 42276507 | Biomarker + Complications | Oxidative-stress profiling + retinal imaging |
| 42270051 | Biomarker + Microbiome | *L. casei* Zhang, hippocampal metabolism, T2DM |
| 42268809 | Biomarker + Microbiome | Microbiome-informed prediction of pregnancy complications |
| 42254168 | T2D Remission + icodec | Once-weekly insulin icodec clinical implications |

**Tracked-therapy mentions:** teplizumab appears in 4 recent papers (incl. a CGM treatment-response paper, NCT-linked, and a Stage-3 T1D efficacy/safety systematic review — both directly relevant given the FDA approval). Retatrutide, orforglipron, icodec, CagriSema each surface in recent literature.

**Volume:** PubMed snapshot diff (Jun 11→12) showed +39 / −37 papers — normal churn. No domain spiking abnormally.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (regenerated 2026-06-14) — **⚠ note: underlying counts date to 2026-04-20.** Validation level: **BRONZE** (single analytical source, expert confirmation pending), per Research Doctrine.

**Top 5 under-researched intersections (Gap Score 100, joint pubs 0–1):**

1. **Beta Cell Regen × Health Equity** (0 joint) — equity analysis of emerging cell therapies is absent
2. **Insulin Resistance × Islet Transplant** (1 joint) — IR in graft recipients barely studied
3. **Islet Transplant × Drug Repurposing** (0 joint) — computational screening of immunosuppressants for islet protection unexplored
4. **Islet Transplant × Health Equity** (0 joint) — access-equity research absent
5. **Gene Therapy × LADA** (0 joint) — no crossover work

**Alignment with Tier 1 contribution areas (from Research Doctrine):**

The gap rankings cluster hard onto two Tier 1 strengths:
- **Drug Repurposing Computational Screening (Tier 1, score 18/20)** — directly maps to gaps #3, #8 (Glucokinase × Repurposing), #12, #13. This is a "we have the tools + real gap" zone.
- **Epidemiological / Health Equity analysis (Tier 1, score 17/20)** — maps to gaps #1, #4, #7, #9, #12, #14. Equity is the single most recurring axis in the top-15 gaps.

These two intersections — **drug repurposing for islet protection** and **equity analysis of cell/advanced therapies** — are where the doctrine's capability and the data's gap signal coincide. Strongest computational-contribution candidates.

---

## Breaking News (web check, last 7 days)

All three items directly involve hub-tracked therapies and tie to **ADA Scientific Sessions 2026 (New Orleans)**.

1. **[Certain] FDA approves teplizumab (Tzield, Sanofi) for children 8+ with stage 3 T1D — June 13, 2026.** Went through the FDA's expedited review program; decision came after the missed April 21 goal date. *Direct hit on a tracked therapy and on the existing `teplizumab_sNDA_decision_prep.md`.* (STAT)
2. **[Certain] Retatrutide (Eli Lilly) TRIUMPH-1 Phase 3 results — June 6, 2026.** Triple GIP/GLP-1/glucagon agonist; ~70 lb mean weight loss in obesity cohort, plus improvements in OSA and knee OA pain. Presented at ADA 2026. (ADA / BioSpace / PRNewswire)
3. **[Certain] Novo Nordisk Reimagine 1–3 Phase 3 results — June 7, 2026.** Significant HbA1c and bodyweight reductions; Reimagine 1 & 2 published in *Lancet Diabetes & Endocrinology*, Reimagine 3 in *The Lancet*. (Insider Monkey / pharmaphorum)

Per Research Doctrine, these are external primary/secondary sources — log as **SILVER** (peer-reviewed publication or regulatory action) pending entry into the tracker with PMIDs/DOIs.

---

## Recommended Actions

**High priority (this week):**
1. **Update the tracker + close the teplizumab prep.** Record the FDA pediatric approval (2026-06-13) in `Diabetes_Research_Tracker.xlsx` and mark `teplizumab_sNDA_decision_prep.md` as resolved. Pull the two recent teplizumab PubMed papers (PMID 42221148 systematic review; 42267680 CGM response) into the paper library.
2. **Re-run the gap analysis.** `python project1_literature_gap_analysis.py` — underlying data is 56 days old (2026-04-20). Rankings should not be cited as current until refreshed.
3. **Refresh PubMed alerts.** `python baseline_pubmed_alerts.py` — last run 2026-06-12 (3 days stale), and ADA 2026 publications (retatrutide, Reimagine) will land in MEDLINE shortly; you'll want them captured.

**Medium priority:**
4. **Capture ADA 2026 Phase 3 results.** Add retatrutide TRIUMPH-1 and Novo Reimagine 1–3 to the trial/results notes; cross-link to NCT06297603 / NCT06260722 (retatrutide) and NCT05813912 (Novo weekly insulin, results posted 6/03).
5. **Review new orforglipron Phase 3 NCT07613307** and the orforglipron-vs-dapagliflozin head-to-head paper (PMID 42259339) — relevant to T2D GLP-1 and pharmacogenomics domains.
6. **Pursue the Tier 1 / top-gap overlap.** The two highest-leverage computational targets are *Islet Transplant × Drug Repurposing* (gap #3) and *equity of cell/advanced therapies* (gaps #1, #4, #7). Both already have partial scaffolding in the hub (`islet_repurposing_*` outputs, `Trial_Equity_Mapper.html`).

**Housekeeping:**
7. Close Excel / clear the `.~lock.Diabetes_Research_Tracker.xlsx#` lock file before the next scripted tracker update, or writes may fail.

---

## Notes & Caveats

- This was a **read-only review run** — no existing files were modified.
- Gap classifications are **BRONZE**; the FDA approval is **CERTAIN**; ADA Phase 3 results are **CERTAIN** as reported but should be logged **SILVER** until PMIDs/DOIs are captured in the hub.
- The hub monitor's own snapshot diff confirms the trial dataset is stable day-over-day; the meaningful movement this period is **external** (ADA + FDA), not in the local snapshots.

*Generated by automated Hub Monitor review — 2026-06-15.*
